Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

Conditions

• Chronic Granulomatous Disease (CGD)

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Study Details

This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.

Key Dates

Start date

Nov 18, 2024

Status verified

Feb 2026

Primary completion

Jun 30, 2026

Completion

Jun 30, 2026

Study Design

Enrollment

60 participants (estimated)

Primary Outcome Measure

Total adenoviral-specific antibody (TAb) titer [ Time Frame: 1 Day ]

Central Contacts

• Andrew Dietz, MD, MSCR
  617-766-3917
  [email protected]

Locations (50)

Find similar trials in Montgomery, AL

Related Studies

• Evaluation of Patients With Immune Function Abnormalities
  Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
• Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
  PHASE1/PHASE2 · Enrolling By Invitation · Paul Szabolcs · Pittsburgh, Pennsylvania
• Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
  PHASE1/PHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
• Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
  PHASE1/PHASE2 · Enrolling By Invitation · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland